LAMTOR3 is a Prognostic Biomarker in Kidney Renal Clear Cell Carcinoma

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Sep 9

PMID 36082464

Authors

Yun Gong

Yue Lv

Fanghua Xu

Youcheng Xiu

Yinhui Lu

Zan Liu

Leihong Deng

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of the study was to investigate the expression of LAMTOR3 in kidney renal clear cell carcinoma (KIRC) and its clinical significance.

Methods: The expression of LAMTOR3 in KIRC and its relationship with clinical features were analyzed using the UALCAN online database. The results were verified using KIRC gene chip data and clinical specimens. The prognosis of KIRC patients was analyzed with the GEPIA2 database. GO, KEGG, and GSEA analyses were conducted to analyze the possible molecular mechanism of LAMTOR3 in KIRC. Immunohistochemical (IHC) and hematoxylin and eosin (H&E) staining were used for histopathological detection.

Results: UALCAN database analysis showed that LAMTOR3 expression in KIRC was significantly lower than in normal kidney tissues and correlated with the clinical stage, pathological grade, and tumor genotype (p < .05). GSE53757 dataset analysis consistently showed that the expression of LAMTOR3 in KIRC was significantly lower than in normal kidney tissues (p < .01). GEPIA2 database analysis indicated that patients with low LAMTOR3 expression had poor overall and disease-free survival rates. GSEA analysis suggested that LAMTOR3 positively regulated the citrate cycle and drug metabolism cytochrome P450 and negatively regulated folate biosynthesis and olfactory transduction. The expression of LAMTOR3 in KIRC was also significantly correlated with immune cell infiltration. Finally, IHC showed that LAMTOR3 expression in the KIRC tissues was lower than in the adjacent normal tissues.

Conclusion: LAMTOR3 expression is significantly lower in KIRC. LAMTOR3 may be a potential marker for KIRC diagnosis and therapy.

Citing Articles

Immunogenic profiling of metastatic uveal melanoma discerns a potential signature related to prognosis.

Wang J, Liu M, Sun J, Zhang Z J Cancer Res Clin Oncol. 2024; 150(1):23.

PMID: 38246894 PMC: 10800307. DOI: 10.1007/s00432-023-05542-z.

Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic Pathways in MCF7 Breast Cancer Cells Transfected for JTB Protein Silencing.

Jayathirtha M, Jayaweera T, Whitham D, Sullivan I, Petre B, Darie C Molecules. 2023; 28(22).

PMID: 38005222 PMC: 10673289. DOI: 10.3390/molecules28227501.

LAMTOR3 is a prognostic biomarker in kidney renal clear cell carcinoma.

Gong Y, Lv Y, Xu F, Xiu Y, Lu Y, Liu Z J Clin Lab Anal. 2022; 36(9):e24648.

PMID: 36082464 PMC: 9459259. DOI: 10.1002/jcla.24648.

References

Breuer E, Fukushiro-Lopes D, Dalheim A, Burnette M, Zartman J, Kaja S . Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling. Cell Death Dis. 2019; 10(3):180. PMC: 6385342. DOI: 10.1038/s41419-019-1429-0. View

Gul A, Rini B . Adjuvant therapy in renal cell carcinoma. Cancer. 2019; 125(17):2935-2944. DOI: 10.1002/cncr.32144. View

Craven R, Vasudev N, Banks R . Proteomics and the search for biomarkers for renal cancer. Clin Biochem. 2012; 46(6):456-65. DOI: 10.1016/j.clinbiochem.2012.11.029. View

Wettersten H, Abu Aboud O, Lara Jr P, Weiss R . Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017; 13(7):410-419. DOI: 10.1038/nrneph.2017.59. View

Hsieh Y, Tung S, Pan H, Yen C, Xu H, Deng Y . Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients. BMC Cancer. 2018; 18(1):508. PMC: 5930761. DOI: 10.1186/s12885-018-4383-9. View

Gray R, Harris G . Renal Cell Carcinoma: Diagnosis and Management. Am Fam Physician. 2019; 99(3):179-184. View

Wu H, Tsai L, Huang C, Hsu P, Chen M, Chen Y . Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. Sci Transl Med. 2021; 13(583). DOI: 10.1126/scitranslmed.abc2823. View

Jun S, Lee S, Kim H, Ng C, Schneider A, Ji H . PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep. 2013; 5(2):314-22. PMC: 4157353. DOI: 10.1016/j.celrep.2013.09.026. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

10.

Roberts-Thomson S, Chalmers S, Monteith G . The Calcium-Signaling Toolkit in Cancer: Remodeling and Targeting. Cold Spring Harb Perspect Biol. 2019; 11(8). PMC: 6671942. DOI: 10.1101/cshperspect.a035204. View

11.

Kwon O, Hong S, Kwon S, Go Y, Oh E, Cha H . BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer. Cancer Lett. 2017; 403:48-58. DOI: 10.1016/j.canlet.2017.05.019. View

12.

Teis D, Taub N, Kurzbauer R, Hilber D, De Araujo M, Erlacher M . p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol. 2006; 175(6):861-8. PMC: 2064696. DOI: 10.1083/jcb.200607025. View

13.

Peng S, Yang S, Bo X, Li F . paraGSEA: a scalable approach for large-scale gene expression profiling. Nucleic Acids Res. 2017; 45(17):e155. PMC: 5737394. DOI: 10.1093/nar/gkx679. View

14.

von Roemeling C, Radisky D, Marlow L, Cooper S, Grebe S, Anastasiadis P . Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014; 74(17):4796-810. PMC: 4154999. DOI: 10.1158/0008-5472.CAN-14-0210. View

15.

Hao J, Cao Y, Yu H, Zong L, An R, Xue Y . Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma. Front Genet. 2021; 12:674613. PMC: 8461076. DOI: 10.3389/fgene.2021.674613. View

16.

Feifei W, HongHai X, YongRong Y, PingXiang W, Jianhua W, XiaoHui Z . FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer progression. Cell Death Dis. 2019; 10(5):351. PMC: 6484082. DOI: 10.1038/s41419-019-1588-z. View

17.

Gong Y, Lv Y, Xu F, Xiu Y, Lu Y, Liu Z . LAMTOR3 is a prognostic biomarker in kidney renal clear cell carcinoma. J Clin Lab Anal. 2022; 36(9):e24648. PMC: 9459259. DOI: 10.1002/jcla.24648. View

18.

Shi K, Fan L, Xu D, Ren L, Wang L, Chen L . MiR-20a suppresses proliferation and facilitates apoptosis of breast cancer cells via the MTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2020; 24(22):11650-11657. DOI: 10.26355/eurrev_202011_23809. View

19.

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View

20.

Liang Z, Guo C, Zou M, Meng P, Zhang T . circRNA-miRNA-mRNA regulatory network in human lung cancer: an update. Cancer Cell Int. 2020; 20:173. PMC: 7236303. DOI: 10.1186/s12935-020-01245-4. View